Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era
J Gottlieb, S Simon, J Barton, M Barnikel, M Bachmann… - Infection, 2023 - Springer
Abstract Purpose Lung transplant (LTx) recipients are at risk for poor outcomes from
coronavirus disease 2019 (COVID-19). The aim of the study was to assess the outcome of …
coronavirus disease 2019 (COVID-19). The aim of the study was to assess the outcome of …
[HTML][HTML] Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection
Background. Lung transplant recipients (LTRs) have an increased risk of COVID-19–related
morbidity and mortality. Tixagevimab-cilgavimab (tix-cil) is a long-acting monoclonal …
morbidity and mortality. Tixagevimab-cilgavimab (tix-cil) is a long-acting monoclonal …
Impaired immune responses and prolonged viral replication in lung allograft recipients infected with SARS-CoV-2 in the early phase after transplantation
OM Glueck, X Liang, I Badell, PR Wratil, A Graf… - Infection, 2024 - Springer
Purpose Lung transplant recipients are at increased risk of severe disease following
infection with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) due to …
infection with severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) due to …
Outcomes of SARS‐CoV‐2 infection among lung transplant recipients: A single center retrospective study
A Casutt, M Papadimitriou‐Olivgeris… - Transplant Infectious …, 2023 - Wiley Online Library
Abstract Background Lung transplant recipients (LTRs) are at increased risk for coronavirus
disease 2019 (COVID‐19)‐associated complications. Methods We aimed to describe the …
disease 2019 (COVID‐19)‐associated complications. Methods We aimed to describe the …
Benefit of monoclonal antibodies in early treatment of COVID-19 after lung transplantation: a retrospective analysis in two centres
J Gottlieb, M Kolditz, N Gade, T Welte… - European Respiratory …, 2022 - Eur Respiratory Soc
Transplant recipients are at risk for poor outcomes from coronavirus disease 2019 (COVID-
19) due to frequent medical comorbidities and presence of immunosuppression …
19) due to frequent medical comorbidities and presence of immunosuppression …
Assessing the post hoc effectiveness of tixagevimab− cilgavimab for prevention of SARS‐CoV‐2 infections in solid organ transplant recipients
Abstract Background Tixagevimab− cilgavimab (Tix‐Cil) was authorized for prophylaxis
against COVID‐19 in immunocompromised patients from December 2021 through January …
against COVID‐19 in immunocompromised patients from December 2021 through January …
COVID-19 infection is mild and has minimal impact on lung function in well vaccinated and widely treated lung transplant recipients
SL Ennis, BJ Levvey, HV Shingles, SJ Lee… - The Journal of Heart and …, 2024 - Elsevier
Background COVID-19 has become a common infection affecting lung transplant recipients
(LTR), who are at high risk for poor outcomes. Outcomes early in the pandemic were poor …
(LTR), who are at high risk for poor outcomes. Outcomes early in the pandemic were poor …
Effects of anti-COVID-19 vaccination and pre-exposure prophylaxis with tixagevimab-cilgavimab in kidney and liver transplant recipients
R Angelico, F Romano, L Coppola, M Materazzo… - Medicina, 2023 - mdpi.com
Background and Objectives: Underpowered immune response to vaccines against SARS-
CoV-2 was observed in solid organ transplant (SOT) recipients. A novel combination of …
CoV-2 was observed in solid organ transplant (SOT) recipients. A novel combination of …
Management of immunosuppression in lung transplant recipients and COVID-19 outcomes: an observational retrospective cohort-study
H Bes-Berlandier, B Coiffard, J Bermudez… - BMC Infectious …, 2024 - Springer
Background The aim of this study was to assess the impact of immunosuppression
management on coronavirus disease 2019 (COVID-19) outcomes. Methods We performed a …
management on coronavirus disease 2019 (COVID-19) outcomes. Methods We performed a …
Perivaccination antimetabolite hold and third dose of SARS-CoV-2 vaccine in lung transplant recipients: preliminary report
We and others have previously reported suboptimal antibody responses in lung transplant
recipients (LTRs) after 2 doses of SARS-CoV-2 mRNA vaccine. 1, 2 Immunosuppressive …
recipients (LTRs) after 2 doses of SARS-CoV-2 mRNA vaccine. 1, 2 Immunosuppressive …
相关搜索
- sars cov lung transplantation
- omicron era lung transplantation
- sars cov omicron era
- sars cov tixagevimab cilgavimab
- covid 19 lung transplantation
- perceptions of risk pre exposure
- monoclonal antibodies lung transplantation
- retrospective analysis lung transplantation
- early treatment lung transplantation
- sars cov early phase